- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
LONG-TERM HEALTH STATE OF CHILDREN BORN FROM IBD MOTHERS EXPOSED TO ANTI-TNF TREATMENT DURING PREGNANCY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2462; Introduction: Infliximab (IFX), adalimumab (ADL) and golimumab (GLM) are anti-TNF inhibitors of IgG1 class which do not cross the placenta until the 3nd trimester of the pregnancy; therefore, they are considered a safe treatment for the foetus during the 1st and 2nd trimester of the pregnancy. In this small, single-centre, prospective study, treatment with IgG1-anti-TNF agents until the 26th gestational week does not seem to be related with later development, response to vaccinations, or any later adverse life events.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
FUNCTIONAL RARE VARIANTS INFLUENCE THE CLINICAL RESPONSE TO ANTI-TNF THERAPY IN CROHN'S DISEASE (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2440; Cell-type enrichment analysis suggests that the gut mucosa and CD8+ T cells are the main mediators of this response. These findings provide new insights into the underlying heterogeneity of CD, revealing the basis of TNF-dependent biological mechanisms
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
PRESENCE OF ANXIETY AND DEPRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ALBANIA (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2409; A significant number of patients with IBD, suffer from depression and/or anxiety and this has an important impact on their quality of life. Patients with a severe disease activity are at a higher risk for anxiety and depression and this may suggest that it can be important to start screeningall the IBD patients with this questionnaire in order to evaluate them and eventually refer them to the psychiatrists.
- |||||||||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
HISTOLOGIC IMPROVEMENT WITH VEDOLIZUMAB VS ADALIMUMAB IN ULCERATIVE COLITIS: RESULTS FROM VARSITY (C2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2071; P3 These data support the use of VDZ over ADA in UC. a Adjusted treatment difference and nominal P value: based on the Cochran-Mantel-Haenszel method, stratified by concomitant use of oral corticosteroids (Yes/No) and prior use of anti-TNF therapy (Yes/No); vedolizumab versus adalimumab.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
SPACING THE ADMINISTRATION INTERVAL OF ANTI-TNF AGENTS: A VALID STRATEGY FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE? (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1690; Aims & Aim : To describe the clinical outcomes of IBD patients treated with anti-TNF agents by means of a spacing schedule (administration interval greater than 8 weeks for infliximab or 2 weeks for adalimumab). Anti-TNF administration at longer intervals than those provided in the data sheet of the drug can be a convenient and cheaper alternative, particularly effective in patients in whom anti-TNF treatment was early initiated (within 5 years from disease diagnosis) and once deep remission has been achieved.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
META-ANALYSIS: DEEP REMISSION IN IBD WITH ANTI-TNF AGENTS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1676; Anti-TNF agents achieved deep remission in IBD in 37.7% of patients, with rates similar between adalimumab and infliximab. Unfortunately, a lack of available trials precludes the comparison of IFX and ADA in UC and CD.
- |||||||||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
INTERLEUKINS LEVELS: ARE WE ON THE ROAD TO TAILORED THERAPY IN INFLAMMATORY BOWEL DISEASE? (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1605; IFN-g and TGF-b1 may be useful to identify AZA responders and IL8 and IL6 levels could be good predictors of response to both biological and immunosuppressive drugs. Our study is a first step for tailored therapy in IBD patients.
- |||||||||| Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Treatment aims of therapeutic drug monitoring (C3) - Aug 18, 2019 - Abstract #UEGW2019UEGW_24; In the recent pediatric PAILOT trial, a proactive dose-adjustment of adalimumab based on TDM and inflammatory markers was superior to conventional therapy for improving long-term outcomes of CD patients. More trials on 'proactive TDM' are eagerly awaited.
- |||||||||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Journal: Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease (Pubmed Central) - Aug 17, 2019 In light of recent literature, this case report shows that chronic granulomatous disease should be considered as a differential diagnosis to therapy refractory IBD. This is the case, especially in young patients, when recurrent bacterial lesions caused by intestine-atypical pathogens appear.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. (Pubmed Central) - Aug 15, 2019 Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study. No abstract available
|